Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 1.1 CAD 0.92% Market Closed
Market Cap: 314.4m CAD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+150%
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

EDT Price Targets Summary
Spectral Medical Inc

Wall Street analysts forecast EDT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDT is 2.75 CAD with a low forecast of 2.73 CAD and a high forecast of 2.84 CAD.

EDT Lowest Forecast
Wall Street Target
2.73 CAD
148% Upside
EDT Average Forecast
Wall Street Target
2.75 CAD
150% Upside
EDT Highest Forecast
Wall Street Target
2.84 CAD
158% Upside
Lowest
Price Target
2.73 CAD
148% Upside
Average
Price Target
2.75 CAD
150% Upside
Highest
Price Target
2.84 CAD
158% Upside
Spectral Medical Inc Competitors:
Price Targets
MRUS
Merus NV
38% Upside
4593
Healios KK
5% Downside
C
COYA
Coya Therapeutics Inc
179% Upside
CRNX
Crinetics Pharmaceuticals Inc
138% Upside
MRUS
Merus NV
38% Upside
4593
Healios KK
5% Downside
C
COYA
Coya Therapeutics Inc
179% Upside
CRNX
Crinetics Pharmaceuticals Inc
138% Upside
D
CRVO
Diffusion Pharmaceuticals Inc
78% Upside
6160
Beigene Ltd
20% Upside
NGNE
Neurogene Inc
138% Upside
GLPG
Galapagos NV
8% Upside

Revenue
Forecast

Revenue Estimate
Spectral Medical Inc

For the last 13 years the compound annual growth rate for Spectral Medical Inc's revenue is 0%. The projected CAGR for the next 1 year is 6%.

0%
Past Growth
6%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Spectral Medical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Spectral Medical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
What are analyst estimates?

See Also

Summary
EDT intrinsic value, competitors valuation, and company profile.
DCF Valuation
EDT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EDT stock valuation using valuation multiples.
Wall Street Estimates
EDT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EDT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EDT's stock price target?
Price Target
2.75 CAD

According to Wall Street analysts, the average 1-year price target for EDT is 2.75 CAD with a low forecast of 2.73 CAD and a high forecast of 2.84 CAD.

What is Spectral Medical Inc's Revenue forecast?
Projected CAGR
6%

For the last 13 years the compound annual growth rate for Spectral Medical Inc's revenue is 0%. The projected CAGR for the next 1 year is 6%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 275,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.